avalo therapeutics inc - AVTX
AVTX
Close Chg Chg %
18.37 0.19 1.03%
Closed Market
18.56
+0.19 (1.03%)
Volume: 131.67K
Last Updated:
Dec 29, 2025, 4:00 PM EDT
Company Overview: avalo therapeutics inc - AVTX
AVTX Key Data
| Open $18.27 | Day Range 18.10 - 18.61 |
| 52 Week Range 3.39 - 20.72 | Market Cap $333.12M |
| Shares Outstanding 18.13M | Public Float 15.43M |
| Beta 0.86 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$8.73 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 344.52K |
AVTX Performance
| 1 Week | 1.03% | ||
| 1 Month | -2.32% | ||
| 3 Months | 38.51% | ||
| 1 Year | 122.81% | ||
| 5 Years | -99.76% |
AVTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About avalo therapeutics inc - AVTX
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
AVTX At a Glance
Avalo Therapeutics, Inc.
1500 Liberty Ridge Drive
Wayne, Pennsylvania 19087
| Phone | 1-410-522-8707 | Revenue | 441.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -35,129,000.00 | |
| Sector | Health Technology | Employees | 23 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
AVTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 126.30 |
| Price to Book Ratio | 0.585 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.866 |
| Enterprise Value to Sales | -172.22 |
| Total Debt to Enterprise Value | -0.038 |
AVTX Efficiency
| Revenue/Employee | 19,173.913 |
| Income Per Employee | -1,527,347.826 |
| Receivables Turnover | 0.722 |
| Total Asset Turnover | 0.005 |
AVTX Liquidity
| Current Ratio | 19.955 |
| Quick Ratio | 19.955 |
| Cash Ratio | 19.334 |
AVTX Profitability
| Gross Margin | 144.671 |
| Operating Margin | -9,267.80 |
| Pretax Margin | -7,939.909 |
| Net Margin | -7,965.76 |
| Return on Assets | -40.913 |
| Return on Equity | -50.064 |
| Return on Total Capital | -25.84 |
| Return on Invested Capital | -48.105 |
AVTX Capital Structure
| Total Debt to Total Equity | 2.193 |
| Total Debt to Total Capital | 2.146 |
| Total Debt to Total Assets | 1.936 |
| Long-Term Debt to Equity | 1.766 |
| Long-Term Debt to Total Capital | 1.729 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Avalo Therapeutics Inc - AVTX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 5.40M | 18.05M | 1.92M | 441.00K | |
Sales Growth
| -19.42% | +234.40% | -89.34% | -77.08% | |
Cost of Goods Sold (COGS) incl D&A
| 3.04M | 3.47M | 1.28M | (197.00K) | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.66M | 166.00K | 158.00K | 169.00K | |
Depreciation
| 109.00K | 128.00K | 158.00K | 169.00K | |
Amortization of Intangibles
| - | - | 1.55M | 38.00K | - |
COGS Growth
| +48.88% | +14.25% | -63.02% | -115.34% | |
Gross Income
| 2.36M | 14.58M | 640.00K | 638.00K | |
Gross Income Growth
| -49.35% | +518.02% | -95.61% | -0.31% | |
Gross Profit Margin
| +43.70% | +80.77% | +33.26% | +144.67% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 84.49M | 52.02M | 24.08M | 41.51M | |
Research & Development
| 59.84M | 31.31M | 13.78M | 24.44M | |
Other SG&A
| 24.66M | 20.71M | 10.30M | 17.07M | |
SGA Growth
| +62.64% | -38.43% | -53.70% | +72.35% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 4.63M | (2.54M) | - |
EBIT after Unusual Expense
| (82.13M) | (37.44M) | (28.07M) | (38.33M) | |
Non Operating Income/Expense
| (20.00K) | (20.00K) | (42.00K) | 3.31M | |
Non-Operating Interest Income
| - | - | - | 3.32M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 2.39M | 4.17M | 3.42M | |
Interest Expense Growth
| - | - | +74.40% | -18.06% | - |
Gross Interest Expense
| - | 2.39M | 4.17M | 3.42M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (84.55M) | (41.63M) | (31.53M) | (35.02M) | |
Pretax Income Growth
| -25.86% | +50.76% | +24.26% | -11.05% | |
Pretax Margin
| -1,566.23% | -230.62% | -1,638.77% | -7,939.91% | |
Income Tax
| (196.00K) | 28.00K | 14.00K | 114.00K | |
Income Tax - Current - Domestic
| - | - | - | (218.00K) | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 22.00K | 28.00K | 14.00K | 114.00K | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (84.35M) | (41.66M) | (31.54M) | (35.13M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (84.35M) | (41.66M) | (31.54M) | (35.13M) | |
Net Income Growth
| -31.01% | +50.61% | +24.28% | -11.37% | |
Net Margin Growth
| -1,562.60% | -230.78% | -1,639.50% | -7,965.76% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (84.35M) | (41.66M) | (31.54M) | (35.13M) | |
Preferred Dividends
| - | - | - | (1.50M) | - |
Net Income Available to Common
| (82.85M) | (41.66M) | (31.54M) | (35.13M) | |
EPS (Basic)
| -2388.7296 | -1062.6504 | -113.5792 | -7.9367 | |
EPS (Basic) Growth
| +3.90% | +55.51% | +89.31% | +93.01% | |
Basic Shares Outstanding
| 34.68K | 39.20K | 277.73K | 4.43M | |
EPS (Diluted)
| -2388.7296 | -1062.6504 | -113.5792 | -20.9087 | |
EPS (Diluted) Growth
| +3.90% | +55.51% | +89.31% | +81.59% | |
Diluted Shares Outstanding
| 34.68K | 39.20K | 277.73K | 7.50M | |
EBITDA
| (80.48M) | (37.27M) | (23.29M) | (40.70M) | |
EBITDA Growth
| -77.07% | +53.68% | +37.53% | -74.79% | |
EBITDA Margin
| -1,490.87% | -206.49% | -1,210.29% | -9,229.48% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 33.714 | |
| Number of Ratings | 9 | Current Quarters Estimate | -1.366 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -6.632 | |
| Last Quarter’s Earnings | -2.19 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -20.91 | Next Fiscal Year Estimate | -5.50 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 6 | 8 | 6 |
| Mean Estimate | -1.37 | -1.41 | -6.63 | -5.50 |
| High Estimates | -0.94 | -0.98 | -5.84 | -3.93 |
| Low Estimate | -1.93 | -1.94 | -7.43 | -7.48 |
| Coefficient of Variance | -24.39 | -27.45 | -8.28 | -29.19 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Avalo Therapeutics Inc - AVTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Avalo Therapeutics Inc - AVTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 2, 2025 | Aaron Kantoff Director | 3,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Christopher Sullivan Chief Financial Officer | 48,400 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Christopher Sullivan Chief Financial Officer | 16,921 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.46 per share | 143,151.66 |
| Apr 2, 2025 | Christopher Sullivan Chief Financial Officer | 24,206 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Mitchell Chan Director | 6,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Mitchell Chan Director | 3,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Samantha Truex Director | 6,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Samantha Truex Director | 3,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Aaron Kantoff Director | 6,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | June Sherie Almenoff Director | 3,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Garry Arthur Neil Chief Executive Officer | 129,733 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Garry Arthur Neil Chief Executive Officer | 47,140 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.46 per share | 398,804.40 |
| Apr 2, 2025 | Garry Arthur Neil Chief Executive Officer | 64,927 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Jonathan H. Goldman Director | 6,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Jonathan H. Goldman Director | 3,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Gilla Kaplan Director | 6,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Gilla Kaplan Director | 3,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | June Sherie Almenoff Director | 6,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |